Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 2 3Phase 3 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 591Neoplasms 296Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 182Lung Neoplasms 150Neoplasm Metastasis 139Leukemia, Myeloid, Acute 126Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 63

Interventions

rasburicase 1Urate Oxidase 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Hyperuricemia × Clear all
NCT00921375 2014-12-12

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Virchow Group

Phase 3 Completed
100 enrolled

Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡